Company

Onconova Therapeutics, Inc.

Headquarters: Newtown, PA, United States

Employees: 11

CEO: Dr. Steven M. Fruchtman M.D.

NASDAQ: ONTX +0.45%

Market Cap

$15.6 Million

USD as of Jan. 1, 2024

Market Cap History

Onconova Therapeutics, Inc. market capitalization over time

Evolution of Onconova Therapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Onconova Therapeutics, Inc.

Detailed Description

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Onconova Therapeutics, Inc. has the following listings and related stock indices.


Stock: NASDAQ: ONTX wb_incandescent

Details

Headquarters:

375 Pheasant Run

Newtown, PA 18940

United States

Phone: 267 759 3680

Fax: 267 759 3681